Interim – Page 2 – Alligator Bioscience

2022-07-12

Regulatory

Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2022-04-27

Regulatory

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...

2022-02-112022-05-17

Regulatory

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...

2021-10-21

Regulatory

First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...

2021-07-13

Regulatory

Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...

2021-04-27

Regulatory

High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...

2021-02-26

Regulatory

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...

2020-10-22

Regulatory

Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...

2020-07-13

Regulatory

Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinica ...